Serac Life Sciences Limited (SLS) announces the formation of a new company, Serac Healthcare Limited (SHC), which will develop and commercialise a novel molecular imaging agent for the detection of disease activity in rheumatoid arthritis (RA). SHC, a wholly-owned subsidiary of SLS, has acquired the molecular imaging agent maraciclatide from GE Healthcare. The goal of the company is to enable rheumatologists to “see disease activity” in the joints, informing clinicians and helping them deliver personalised care to their patients.
Maraciclatide is a molecular imaging agent which binds to a protein (αVβ3 integrin) found in abundance in joints affected by RA but which is largely absent in healthy joints. Preliminary clinical trial results are extremely encouraging and SHC plans to complete further studies in RA and other conditions in which αVβ3 integrin is over-expressed (e.g. Psoriatic Arthritis [PS], Enthesitis, Ankylosing Spondylitis [AS], tumours, inflammatory cardiovascular conditions and cardiac remodelling). The company intends to seek worldwide regulatory approvals for maraciclatide.
Serac Life Sciences (SLS) has been established with investment from Serac Limited (Serac) - a strategy, transformation and innovation consultancy with deep experience in the Life Sciences and Healthcare Industries. Serac was established in 1992 and has been helping businesses around the globe unlock their potential and value ever since. Serac's investment in and ongoing support of SLS brings together profound expertise in insight and people driven approaches to strategy and innovation, in combination with a leadership team with over 80 years experience in the global development and successful commercialization of molecular imaging technologies. The acquisition of maraciclatide is the first step towards building a portfolio from hitherto dormant assets which we believe can create value by making a substantial difference to patients and healthcare systems around the world.